Literature DB >> 30664702

Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial.

Shokei Kim-Mitsuyama1, Hirofumi Soejima2,3, Osamu Yasuda4, Koichi Node5, Hideaki Jinnouchi6, Eiichiro Yamamoto2, Taiji Sekigami7, Hisao Ogawa8, Kunihiko Matsui9.   

Abstract

To investigate whether anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients, we performed a subgroup analysis of the ATTEMPT-CVD study based on baseline hemoglobin. The ATTEMPT-CVD study was a multicenter, prospective, randomized study of hypertensive outpatients that compared the efficacy of angiotensin receptor blocker (ARB)-based antihypertensive treatment with non-ARB antihypertensive treatment over 3 years. In the present subanalysis, ATTEMPT-CVD study participants (n = 1213) were categorized into the anemic group and nonanemic group according to their baseline hemoglobin. We compared the anemic and nonanemic groups mainly in regard to the incidence of cardiovascular and renal events and blood pressure. We also performed a multivariable Cox proportional hazards analysis to determine the prognostic factors that were independently associated with cardiovascular and renal events. Of the 1213 patients enrolled in the ATTEMPT-CVD, 194 patients had anemia (mostly mild anemia) and 1019 patients did not. Blood pressure was well-controlled during the 3 years of antihypertensive therapy in both the anemic and nonanemic groups. However, the incidence of cardiovascular and renal events was significantly greater in the anemic group than in the nonanemic group (HR = 1.945: 95%CI 1.208-3.130; P = 0.0062). Even after adjustment, anemia was independently associated with cardiovascular and renal events (HR = 1.816: 95%CI 1.116-2.955; P = 0.0163) in overall hypertensive patients with well-controlled blood pressure. Anemia, even mild anemia, is an independent risk factor for cardiovascular and renal events in hypertensive outpatients whose blood pressure is well-controlled. Thus, anemia may be a novel therapeutic target for cardiovascular and renal diseases in hypertensive outpatients with anemia.

Entities:  

Keywords:  Anemia; cardiovascular disease; hemoglobin; hypertension; renal disease

Year:  2019        PMID: 30664702     DOI: 10.1038/s41440-019-0210-1

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  5 in total

1.  Feasibility of community health workers using a clinical decision support system to screen and monitor non-communicable diseases in resource-poor settings: study protocol.

Authors:  Sojib Bin Zaman; Roger G Evans; Rajkumari Singh; Akash Singh; Parul Singh; Rajesh Singh; Amanda G Thrift
Journal:  Mhealth       Date:  2021-01-20

2.  Association between metabolic parameters and risks of anemia and electrolyte disturbances among stages 3-5 chronic kidney disease patients in Taiwan.

Authors:  Adi Lukas Kurniawan; Mei-Yun Chin; Ya-Lan Yang; Chien-Yeh Hsu; Rathi Paramastri; Hsiu-An Lee; Po-Yuan Ni; Jane C-J Chao
Journal:  BMC Nephrol       Date:  2021-11-17       Impact factor: 2.388

Review 3.  Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin.

Authors:  Ramy M Hanna; Elani Streja; Kamyar Kalantar-Zadeh
Journal:  Adv Ther       Date:  2020-10-29       Impact factor: 3.845

4.  Additive Effect of Sarcopenia and Anemia on the 10-Year Risk of Cardiovascular Disease in Patients with Type 2 Diabetes.

Authors:  Feihui Zeng; Lingning Huang; Yongze Zhang; Xinyu Hong; Suiyan Weng; Ximei Shen; Fengying Zhao; Sunjie Yan
Journal:  J Diabetes Res       Date:  2022-01-24       Impact factor: 4.011

5.  Sex-Specific Association Between Iron Status and the Predicted 10-Year Risk for Atherosclerotic Cardiovascular Disease in Hypertensive Patients.

Authors:  Liping Hao; Xiaolin Peng; Juan Zhou; Rui Zhao; Dongxia Wang; Qin Gao; Dan Zhao; Binfa Ouyang
Journal:  Biol Trace Elem Res       Date:  2022-01-24       Impact factor: 4.081

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.